April 25, 2019
1 min read

FDA approves Skyrizi for moderate to severe plaque psoriasis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

AbbVie announced that the FDA has approved Skyrizi, an interleukin-23 inhibitor for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

The recommended dose for Skyrizi (risankizumab-rzaa) is 150 mg, administered by two subcutaneous injections every 12 weeks following two initiation doses at week 0 and week 4, according to a company press release.

The interleukin-23 (IL-23) inhibitor selectively blocks IL-23 by binding to its p19 subunit.

The treatment may be administered in-office or by self-injection, according to the press release.

Four randomized, placebo and/or active-controlled studies assessed the treatment in adults with moderate to severe plaque psoriasis: ultlMMa-1, ultlMMa-2, IMMhance and IMMvent.

In ultlMMa-1 and ultlMM-2 at 16 weeks, Psoriasis Area and Severity Index (PASI) 90 was achieved in 75% of those treated with risankizumab-rzaa compared with 5% and 2% (P < .001) of patients receiving placebo, respectively, according to the press release.

In ultlMMa-1 and ultlMM-2, PASI 100 was achieved in 36% and 51% of patients treated with risankizumab-rzaa compared with 0% and 2% (P < .001) receiving placebo, respectively.

In the same studies at 1 year, 82% and 81% of people treated with risankizumab-rzaa achieved PSAI 90 (P < .001), respectively.

In patients treated with risankizumab-rzaa who achieved PASI 90 at week 16, 88% of patients maintained the response at 1 year. In those who achieved PASI 100 at week 16 with treatment, 80% of patients maintained the response at 1 year.

According to the release, the most common adverse events associated with the treatment include respiratory infection (13%), headaches (3.5%), fatigue (2.5%), injection site reactions (1.5%) and tinea infections (1.1%).

Skyrizi has also been approved in Japan and is currently under evaluation by the European Medicines Agency.